Annual report [Section 13 and 15(d), not S-K Item 405]

General (Details)

v3.25.1
General (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Feb. 27, 2025
Aug. 08, 2024
Jul. 15, 2024
Jul. 09, 2024
Mar. 15, 2024
Oct. 29, 2019
Dec. 31, 2024
Dec. 31, 2023
General [Line Items]                
Total shares issued and outstanding           65.00%    
Aggregate gross proceeds             $ 28,745
Accumulated deficit   $ (180,697)         $ (180,697) (162,970)
Exercise price per share (in Dollars per share)             $ 0.01  
Goodwill value             $ 801  
Increase to goodwill             300  
Goodwill impairment             801
IPR&D impairment             $ 3,237
Percentage of discount for lack of marketability             9.40%  
Impairments loss related to long-lived assets             $ 4,046
In Process Research and Development [Member]                
General [Line Items]                
Intangible assets             15,287  
Goodwill value             501  
IPR&D impairment             $ 3,237  
Merger Warrants [Member]                
General [Line Items]                
Aggregate shares (in Shares)         216,650      
Exercise price per share (in Dollars per share)             $ 50  
Warrant expire date             Mar. 15, 2024  
Warrant [Member]                
General [Line Items]                
Warrant expire date       Jan. 28, 2027        
Private Placement Warrants [Member]                
General [Line Items]                
Exercise price per share (in Dollars per share) [1]             $ 2.31  
Warrant expire date [1]             Mar. 15, 2024  
Common Stock [Member]                
General [Line Items]                
Aggregate shares (in Shares) [2],[3]               1,599,746
Reverse stock split   1-for-10            
Redeemable convertible preferred shares (in Shares)         916,497      
Conversion of shares (in Shares)         100      
Converted shares (in Shares)     10,915,200          
Common Stock [Member] | Merger Warrants [Member]                
General [Line Items]                
Exercise price per share (in Dollars per share)       $ 50        
APT’s Stockholders [Member]                
General [Line Items]                
Acquisition owned percentage             45.00%  
Transaction costs             $ 888  
APT’s Stockholders [Member] | Private Placement Warrants [Member]                
General [Line Items]                
Acquisition owned percentage             55.00%  
BiomX Israel [Member]                
General [Line Items]                
Aggregate shares (in Shares)           1,506,906    
Subsequent Event [Member]                
General [Line Items]                
Funds from operations $ 12,000              
Redeemable Convertible Preferred Shares [Member]                
General [Line Items]                
Redeemable convertible preferred shares (in Shares)         40,470      
Converted shares (in Shares)     109,152          
Percentage of discount for lack of marketability       14.90%        
Private Placement [Member]                
General [Line Items]                
Aggregate gross proceeds         $ 50,000   $ 50,000  
[1] On February 25, 2025, the Private Placement Warrants were repriced to an exercise price of $0.93 per share in connection with a Securities Purchase Agreement the Company entered into. See Note 19 for further information.
[2] See note 12A.
[3] See note 7A.